Ruggieri M - Search Results

1

Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients.

Ruggieri M, Pica C, Lia A, Zimatore GB, Modesto M, Di Liddo E, Specchio LM, Livrea P, Trojano M, Avolio C. Ruggieri M, et al. J Neuroimmunol. 2008 Jul 15;197(2):140-6. doi: 10.1016/j.jneuroim.2008.04.032. Epub 2008 Jun 13. J Neuroimmunol. 2008. PMID: 18555539

2

Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.

Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M. Avolio C, et al. Among authors: ruggieri m. J Neuroimmunol. 2003 Mar;136(1-2):46-53. doi: 10.1016/s0165-5728(03)00006-7. J Neuroimmunol. 2003. PMID: 12620642

3

Glatiramer acetate in multiple sclerosis: a review.

Ruggieri M, Avolio C, Livrea P, Trojano M. Ruggieri M, et al. CNS Drug Rev. 2007 Summer;13(2):178-91. doi: 10.1111/j.1527-3458.2007.00010.x. CNS Drug Rev. 2007. PMID: 17627671 Free PMC article. Review.

4

Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.

Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio LM, Martino G, Trojano M, Furlan R, Avolio C. Caragnano M, et al. Among authors: ruggieri m. J Neuroimmunol. 2012 Apr;245(1-2):93-7. doi: 10.1016/j.jneuroim.2012.02.002. Epub 2012 Feb 26. J Neuroimmunol. 2012. PMID: 22370183

5

Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.

Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, Papa S, Livrea P, Trojano M. Ruggieri M, et al. J Neurol. 2006 Feb;253(2):231-6. doi: 10.1007/s00415-005-0965-y. Epub 2005 Sep 30. J Neurol. 2006. PMID: 16184340

6

The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.

Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. Iaffaldano P, et al. Among authors: ruggieri m. Brain Behav Immun. 2014 Jan;35:176-81. doi: 10.1016/j.bbi.2013.08.009. Epub 2013 Aug 30. Brain Behav Immun. 2014. PMID: 23994630

7

Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.

Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P. Trojano M, et al. Among authors: ruggieri m. Neurology. 1999 Oct 22;53(7):1402-8. doi: 10.1212/wnl.53.7.1402. Neurology. 1999. PMID: 10534242

8

LFA-1 expression on CD4(+)CD45RO(+) peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a.

Avolio C, Ruggieri M, Cafforio P, Giuliani F, Silvestris F, Dammacco F, Livrea P, Trojano M. Avolio C, et al. Among authors: ruggieri m. J Neurol Sci. 2001 May 1;186(1-2):65-73. doi: 10.1016/s0022-510x(01)00506-8. J Neurol Sci. 2001. PMID: 11412874 Clinical Trial.

9

Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system.

Trojano M, Avolio C, Ruggieri M, De Robertis F, Giuliani F, Paolicelli D, Livrea P. Trojano M, et al. Among authors: ruggieri m. Mult Scler. 1998 Feb;4(1):39-44. doi: 10.1177/135245859800400110. Mult Scler. 1998. PMID: 9532592

10

Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.

Trojano M, Avolio C, Ruggieri M, Defazio G, Giuliani F, Paolicelli D, Livrea P. Trojano M, et al. Among authors: ruggieri m. Mult Scler. 1998 Jun;4(3):183-7. doi: 10.1177/135245859800400318. Mult Scler. 1998. PMID: 9762671 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

710 results

Search Page

Filters